Gene Therapy Lyfgenia denied due to quantity / dose limits by State Medicaid (varies)?

State Medicaid (varies)'s specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why State Medicaid Programs Issue Quantity-Limit Denials for Lyfgenia

Quantity-limit denials for Lyfgenia in the Medicaid context arise from a structural mismatch: the program's drug-utilization management system is built around recurring prescription fills, and it may flag a gene therapy administration as exceeding a monthly or annual quantity limit designed for oral or injectable medications taken on a schedule. This is a system-logic error rather than a clinical judgment — Lyfgenia is administered once, which is both the complete course of treatment and the only authorized use under the FDA prescribing label.

Additionally, some state Medicaid programs process gene therapies through specialty pharmacy benefit channels that have their own quantity edits, which may not have been updated to recognize a one-time administration as categorically different from a maintenance therapy.

## Why This Denial Is Appealable

Quantity limits must be clinically grounded. A limit that, when applied literally, denies the only administration authorized under the FDA label for a serious, life-affecting condition has no valid clinical basis. State Medicaid programs are required to cover medically necessary services in sufficient scope and amount — a quantity limit that effectively blocks an FDA-approved one-time gene therapy fails that standard.

## Your Appeal Rights and Timeline

• State Medicaid fair hearing: Request a fair hearing within the deadline stated on the denial notice. State deadlines vary — confirm the specific deadline for your state.
• Expedited hearing: If the patient faces urgent clinical need or treatment is imminently scheduled, request expedited processing.
• Managed care external review: If enrolled in a Medicaid managed care organization, confirm whether the plan's external review process is also available.
• Pre-service resolution: If the administration has not yet occurred, try resolving the quantity-limit edit through the plan's pharmacy prior-authorization process before the service date.

## Documentation to Gather

1. FDA prescribing label: The label section describing the authorized administration — confirming a single administration constitutes the complete course of treatment. 2. Prescriber order: The treating hematologist's order exactly reflecting the label-directed single administration. 3. Specialty pharmacy documentation: A letter from the specialty pharmacy or treatment center confirming that only one administration is planned and that there is no ongoing refill schedule. 4. Medical-necessity letter: The prescriber's statement confirming that the administration is consistent with the FDA-approved indication and that no additional quantity is being requested beyond what the label authorizes.

## Criteria-Mapping Structure

Obtain the state Medicaid program's or managed care plan's quantity-limit policy for Lyfgenia or for gene therapies. Address the logic of the limit's application:

| Quantity-Limit Issue | Clarifying Evidence | |---|---| | Limit designed for refillable prescriptions | FDA label confirms single-administration course | | Administration quantity requested | One administration — matching label exactly | | No ongoing supply or refill requested | Specialty pharmacy letter confirming single event | | Limit application precludes FDA-approved use | Prescriber letter requesting exception as label-consistent |

Frame the appeal around the core argument: applying a recurring-fill quantity limit to a one-time gene therapy is categorically inapplicable, and doing so would effectively deny an FDA-approved treatment for a serious illness without clinical justification.